ITRM Iterum Therapeutics plc
Price (delayed)
$1.13
Market cap
$39.08M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.26
Enterprise value
$60.45M
Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people
Highlights
Iterum Therapeutics's equity has surged by 65% QoQ and by 36% YoY
ITRM's EPS has soared by 57% YoY and by 37% QoQ
ITRM's quick ratio has surged by 76% since the previous quarter but it is down by 23% year-on-year
The debt has soared by 140% YoY and by 103% QoQ
Key stats
What are the main financial stats of ITRM
Market
Valuations
Earnings
Shares outstanding
34.58M
Market cap
$39.08M
Enterprise value
$60.45M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
-$254,000
Operating income
-$18.7M
Net income
-$24.77M
EBIT
-$22.01M
EBITDA
-$21.73M
Free cash flow
-$26.77M
Per share
Balance sheet
Liquidity
EPS
-$1.26
EPS diluted
-$1.26
Free cash flow per share
-$1.36
Book value per share
-$0.15
Revenue per share
$0
TBVPS
$1.26
Total assets
$44.6M
Total liabilities
$48.68M
Debt
$45.53M
Equity
-$4.08M
Working capital
$7.18M
Debt to equity
-11.16
Current ratio
1.41
Quick ratio
1.37
Net debt/EBITDA
-0.98
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-105.1%
Return on equity
N/A
Return on invested capital
-139.8%
Return on capital employed
-81.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ITRM stock price
How has the Iterum Therapeutics stock price performed over time
Intraday
-3.42%
1 week
-10.32%
1 month
-16.3%
1 year
-39.57%
YTD
-36.16%
QTD
-8.13%
Financial performance
How have Iterum Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
-$254,000
Operating income
-$18.7M
Net income
-$24.77M
Gross margin
N/A
Net margin
N/A
The operating income has surged by 61% year-on-year and by 29% since the previous quarter
The net income rose by 35% YoY and by 19% QoQ
Growth
What is Iterum Therapeutics's growth rate over time
Valuation
What is Iterum Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ITRM's EPS has soared by 57% YoY and by 37% QoQ
Iterum Therapeutics's equity has surged by 65% QoQ and by 36% YoY
Efficiency
How efficient is Iterum Therapeutics business performance
The ROIC has dropped by 76% year-on-year but it has increased by 26% since the previous quarter
ITRM's ROA is up by 35% QoQ but it is down by 20% YoY
Dividends
What is ITRM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ITRM.
Financial health
How did Iterum Therapeutics financials performed over time
The total assets is 8% smaller than the total liabilities
The total assets has surged by 180% since the previous quarter and by 70% year-on-year
Iterum Therapeutics's total liabilities has soared by 77% from the previous quarter and by 49% YoY
The debt has soared by 140% YoY and by 103% QoQ
Iterum Therapeutics's equity has surged by 65% QoQ and by 36% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.